$171 Million is the total value of NEXTHERA CAPITAL LP's 39 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 109.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHPG | Buy | Shire PLCsponsored adr | $22,149,000 | +70.5% | 130,000 | +94.0% | 12.98% | +62.7% |
| NVS | New | Novartis AGsponsored adr | $14,422,000 | – | 198,000 | +100.0% | 8.45% | – |
| CELG | New | Celgene Corp | $14,122,000 | – | 122,000 | +100.0% | 8.28% | – |
| ALXN | New | Alexion Pharmaceuticals Inc | $12,235,000 | – | 100,000 | +100.0% | 7.17% | – |
| PFE | Sell | Pfizer Inc | $10,330,000 | -53.4% | 318,051 | -51.4% | 6.06% | -55.5% |
| AZN | New | AstraZeneca PLCsponsored adr | $8,196,000 | – | 300,000 | +100.0% | 4.80% | – |
| HZNP | New | Horizon Pharma Plc | $8,090,000 | – | 500,000 | +100.0% | 4.74% | – |
| AstraZeneca PLCcall | $6,830,000 | -16.9% | 250,000 | 0.0% | 4.00% | -20.7% | ||
| KITE | New | Kite Pharma Inc | $6,726,000 | – | 150,000 | +100.0% | 3.94% | – |
| New | TESARO Incput | $6,724,000 | – | 50,000 | +100.0% | 3.94% | – | |
| ALNY | New | Alnylam Pharmaceuticals Inc | $6,178,000 | – | 165,000 | +100.0% | 3.62% | – |
| NERV | New | Minerva Neurosciences Inc | $5,792,000 | – | 492,958 | +100.0% | 3.40% | – |
| NBIX | New | Neurocrine Biosciences Inc | $4,644,000 | – | 120,000 | +100.0% | 2.72% | – |
| XLRN | Sell | Acceleron Pharma Inc | $4,543,000 | -42.4% | 178,000 | -18.3% | 2.66% | -45.0% |
| INSM | Insmed Inc | $4,261,000 | -8.9% | 322,044 | 0.0% | 2.50% | -13.1% | |
| EIGR | Sell | Eiger BioPharmaceuticals Inc | $3,071,000 | -13.1% | 263,600 | -0.2% | 1.80% | -17.1% |
| ABEO | Buy | Abeona Therapeutics Inc | $2,758,000 | +42.9% | 568,573 | +76.8% | 1.62% | +36.3% |
| ADMS | Sell | Adamas Pharmaceuticals Inc | $2,563,000 | -44.0% | 151,670 | -45.6% | 1.50% | -46.6% |
| FGEN | Sell | FibroGen Inc | $2,482,000 | -6.1% | 116,000 | -9.1% | 1.46% | -10.4% |
| TRVN | Buy | Trevena Inc | $2,345,000 | +16.3% | 398,849 | +33.5% | 1.38% | +11.0% |
| CARA | New | Cara Therapeutics Inc | $2,323,000 | – | 250,000 | +100.0% | 1.36% | – |
| New | NewLink Genetics Corpcall | $2,056,000 | – | 200,000 | +100.0% | 1.20% | – | |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $2,024,000 | -31.1% | 100,000 | -31.6% | 1.19% | -34.3% |
| ZGNX | Sell | Zogenix Inc | $1,823,000 | -38.7% | 150,000 | -42.3% | 1.07% | -41.5% |
| CNCE | Concert Pharmaceuticals Inc | $1,727,000 | +1.8% | 167,866 | 0.0% | 1.01% | -3.0% | |
| PRTK | New | Paratek Pharmaceuticals Inc | $1,540,000 | – | 100,000 | +100.0% | 0.90% | – |
| SGMO | New | Sangamo BioSciences Inc | $1,534,000 | – | 503,000 | +100.0% | 0.90% | – |
| ADXS | Advaxis Inc | $1,432,000 | -33.0% | 200,000 | 0.0% | 0.84% | -36.1% | |
| New | Axovant Sciences Ltdcall | $1,242,000 | – | 100,000 | +100.0% | 0.73% | – | |
| IMDZ | Sell | Immune Design Corp | $1,092,000 | -52.8% | 198,600 | -34.9% | 0.64% | -55.0% |
| CLSD | New | Clearside Biomedical Inc | $1,080,000 | – | 120,763 | +100.0% | 0.63% | – |
| RDHL | New | Redhill Biopharma Ltdsponsored ads | $994,000 | – | 95,000 | +100.0% | 0.58% | – |
| GBT | New | Global Blood Therapeutics Inc | $867,000 | – | 60,000 | +100.0% | 0.51% | – |
| New | Intec Pharma Ltd | $791,000 | – | 138,845 | +100.0% | 0.46% | – | |
| VTGN | VistaGen Therapeutics Inc | $515,000 | -10.4% | 138,132 | 0.0% | 0.30% | -14.4% | |
| New | Amicus Therapeutics Inccall | $497,000 | – | 100,000 | +100.0% | 0.29% | – | |
| VSTM | Verastem Inc | $376,000 | -15.9% | 336,000 | 0.0% | 0.22% | -20.0% | |
| VBLT | Vascular Biogenics Ltd | $162,000 | -6.9% | 33,332 | 0.0% | 0.10% | -11.2% | |
| TCON | New | Tracon Pharmaceuticals Inc | $62,000 | – | 12,714 | +100.0% | 0.04% | – |
| BPMX | Exit | BioPharmX Corp | $0 | – | -57,656 | -100.0% | -0.02% | – |
| OPHT | Exit | Ophthotech Corp | $0 | – | -24,000 | -100.0% | -0.68% | – |
| FOMX | Exit | Foamix Pharmaceuticals Ltd | $0 | – | -125,000 | -100.0% | -0.71% | – |
| AXGT | Exit | Axovant Sciences Ltd | $0 | – | -100,000 | -100.0% | -0.86% | – |
| AERI | Exit | Aerie Pharmaceuticals Inc | $0 | – | -50,000 | -100.0% | -1.16% | – |
| PGNX | Exit | Progenics Pharmaceuticals Inc | $0 | – | -350,000 | -100.0% | -1.36% | – |
| Exit | Neuroderm Ltd | $0 | – | -131,000 | -100.0% | -1.49% | – | |
| CLCD | Exit | CoLucid Pharmaceuticals Inc | $0 | – | -100,000 | -100.0% | -2.34% | – |
| IMMU | Exit | Immunomedics Inc | $0 | – | -1,263,276 | -100.0% | -2.52% | – |
| CLVS | Exit | Clovis Oncology Inc | $0 | – | -120,000 | -100.0% | -2.66% | – |
| LCI | Exit | Lannett Co Inc | $0 | – | -167,000 | -100.0% | -2.73% | – |
| AQXP | Exit | Aquinox Pharmaceuticals Inc | $0 | – | -340,000 | -100.0% | -2.79% | – |
| SGEN | Exit | Seattle Genetics Inc | $0 | – | -111,500 | -100.0% | -3.70% | – |
| GSK | Exit | GlaxoSmithKline PLCsponsored adr | $0 | – | -345,000 | -100.0% | -9.14% | – |
| Exit | SPDR S&P Biotech ETFput | $0 | – | -400,000 | -100.0% | -16.29% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.